GOLD REPORT 2023
INITIAL TREATMENT
More than 80% of patients with COPD present when they are already symptomatic3,4§
RECOMMENDATIONS
LAMA/LABA should be considered the optimal first-line treatment for most patients with COPD (Group B+E)1
LAMA/LABA/ICS should be considered for a few patients in Group E, at initiation of maintenance therapy1,2*†
LABA/ICS use in COPD is not encouraged1‡
Spiolto
SPIOLTO® RESPIMAT® - actively delivered through a soft mist5
Spiolto
Footnotes & References >
PC-CRP-104007 - November 2022 Spiolto